IAM-C1

About Iambic Therapeutics

Iambic Therapeutics is a private, clinical-stage biotech leveraging a proprietary, integrated AI and high-throughput experimentation platform to accelerate drug discovery. Its core technologies, the Enchant multimodal transformer and NeuralPLexer for protein-ligand structure prediction, are designed to overcome key bottlenecks in preclinical research. The company has advanced its lead asset, IAM1363, into Phase 1b studies for HER2-driven cancers and has established a strategic collaboration with Takeda, positioning it as a player in the AI-driven drug discovery space with both an internal pipeline and a platform partnership model.

Therapeutic Areas

Other HR+/HER2- metastatic breast cancer Drugs